V Square Quantitative Management LLC Sells 120 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

V Square Quantitative Management LLC lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,540 shares of the medical equipment provider’s stock after selling 120 shares during the period. V Square Quantitative Management LLC’s holdings in Zimmer Biomet were worth $585,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Asset Management One Co. Ltd. boosted its holdings in Zimmer Biomet by 0.7% in the fourth quarter. Asset Management One Co. Ltd. now owns 81,913 shares of the medical equipment provider’s stock valued at $8,754,000 after acquiring an additional 602 shares in the last quarter. MFG Wealth Management Inc. bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $1,506,000. Van ECK Associates Corp boosted its holdings in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after buying an additional 218,688 shares in the last quarter. Kentucky Trust Co bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $39,000. Finally, Stonebridge Financial Group LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $25,000. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Royal Bank of Canada dropped their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Wells Fargo & Company boosted their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Stifel Nicolaus boosted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Truist Financial restated a “hold” rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Up 0.6 %

ZBH stock opened at $100.52 on Friday. The business’s 50-day moving average is $106.34 and its two-hundred day moving average is $107.72. The company has a market cap of $20.01 billion, a price-to-earnings ratio of 22.59, a P/E/G ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the business earned $2.20 EPS. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.